Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Beasley

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Cancers|September 10, 2021
Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic CarcinomaLaura Feeney, Yatin Jain, Matthew Beasley, et al.
Physics and Imaging in Radiation Oncology|July 26, 2021
Patient position verification in magnetic-resonance imaging only radiotherapy of anal and rectal cancersDavid Bird, Matthew Beasley, Michael G Nix, et al.
Plos One|August 17, 2010
Rad21-cohesin haploinsufficiency impedes DNA repair and enhances gastrointestinal radiosensitivity in miceHuiling Xu, Kuhendra Balakrishnan, Jordane Malaterre, et al.
Blood Advances|September 3, 2020
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphomaArne Kolstad, Tim Illidge, Nils Bolstad, et al.
Thyroid : Official Journal of the American Thyroid Association|August 11, 2023
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine TherapyJon Wadsley, Gemma Ainsworth, Amy Beth Coulson, et al.
The Lancet. Oncology|July 9, 2023
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trialChristopher Nutting, Laura Finneran, Justin Roe, et al.
BMC Cancer|October 8, 2016
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancerImran Petkar, Keith Rooney, Justin W G Roe, et al.
Journal of Medical Genetics|January 28, 2012
Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24Angela M Jones, Kimberley M Howarth, Lynn Martin, et al.
Lancet (London, England)|March 24, 2026
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trialDavid J Thomson, James M Price, Matthew Tyler, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trialChristopher M Nutting, Clare L Griffin, Paul Sanghera, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Cancers|September 10, 2021
Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic CarcinomaLaura Feeney, Yatin Jain, Matthew Beasley, et al.
Physics and Imaging in Radiation Oncology|July 26, 2021
Patient position verification in magnetic-resonance imaging only radiotherapy of anal and rectal cancersDavid Bird, Matthew Beasley, Michael G Nix, et al.
Plos One|August 17, 2010
Rad21-cohesin haploinsufficiency impedes DNA repair and enhances gastrointestinal radiosensitivity in miceHuiling Xu, Kuhendra Balakrishnan, Jordane Malaterre, et al.
Blood Advances|September 3, 2020
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphomaArne Kolstad, Tim Illidge, Nils Bolstad, et al.
Thyroid : Official Journal of the American Thyroid Association|August 11, 2023
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine TherapyJon Wadsley, Gemma Ainsworth, Amy Beth Coulson, et al.
The Lancet. Oncology|July 9, 2023
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trialChristopher Nutting, Laura Finneran, Justin Roe, et al.
BMC Cancer|October 8, 2016
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancerImran Petkar, Keith Rooney, Justin W G Roe, et al.
Journal of Medical Genetics|January 28, 2012
Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24Angela M Jones, Kimberley M Howarth, Lynn Martin, et al.
Lancet (London, England)|March 24, 2026
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trialDavid J Thomson, James M Price, Matthew Tyler, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trialChristopher M Nutting, Clare L Griffin, Paul Sanghera, et al.
Pageof 5